Stryker Co. (NYSE:SYK) Shares Sold by Securian Asset Management Inc.

Securian Asset Management Inc. decreased its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 11.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,426 shares of the medical technology company's stock after selling 2,829 shares during the quarter. Securian Asset Management Inc.'s holdings in Stryker were worth $6,416,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Farmers & Merchants Trust Co of Chambersburg PA increased its stake in shares of Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company's stock worth $27,000 after acquiring an additional 61 shares during the period. Rogco LP acquired a new stake in Stryker in the 4th quarter valued at about $30,000. HBC Financial Services PLLC purchased a new stake in Stryker in the 4th quarter valued at $37,000. Bourgeon Capital Management LLC purchased a new stake in shares of Stryker in the fourth quarter valued at about $37,000. Finally, Operose Advisors LLC increased its stake in Stryker by 308.6% during the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company's stock worth $39,000 after acquiring an additional 108 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on SYK shares. BTIG Research boosted their target price on Stryker from $366.00 to $369.00 and gave the company a "buy" rating in a research report on Wednesday, May 1st. Canaccord Genuity Group raised Stryker from a "hold" rating to a "buy" rating and set a $360.00 price target for the company in a report on Wednesday, January 31st. Stifel Nicolaus raised their price objective on shares of Stryker from $350.00 to $375.00 and gave the stock a "buy" rating in a report on Wednesday, May 1st. UBS Group upped their target price on shares of Stryker from $339.00 to $351.00 and gave the company a "neutral" rating in a report on Wednesday, May 1st. Finally, Canaccord Genuity Group upgraded shares of Stryker from a "hold" rating to a "buy" rating and lifted their price target for the stock from $315.00 to $360.00 in a research note on Wednesday, January 31st. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $365.94.

Insider Transactions at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.90% of the company's stock.

Stryker Price Performance

Shares of Stryker stock traded up $0.70 during trading on Friday, reaching $334.68. The company's stock had a trading volume of 940,474 shares, compared to its average volume of 1,622,308. The company has a market capitalization of $127.50 billion, a P/E ratio of 38.21, a price-to-earnings-growth ratio of 2.61 and a beta of 0.91. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The business has a 50 day moving average price of $342.20 and a 200-day moving average price of $322.20. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.36 by $0.14. The company had revenue of $5.24 billion during the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The company's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period last year, the firm earned $2.14 EPS. As a group, sell-side analysts anticipate that Stryker Co. will post 11.94 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend is Friday, June 28th. Stryker's payout ratio is currently 36.53%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.